Amova Asset Management Americas Inc. Has $84.69 Million Stock Position in Natera, Inc. $NTRA

Amova Asset Management Americas Inc. cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 10.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 423,424 shares of the medical research company’s stock after selling 47,660 shares during the period. Natera comprises approximately 1.2% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 29th biggest position. Amova Asset Management Americas Inc.’s holdings in Natera were worth $84,685,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NTRA. Horizon Investments LLC raised its holdings in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its stake in Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after buying an additional 46 shares in the last quarter. Parallel Advisors LLC grew its position in Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the last quarter. Finally, First Horizon Corp raised its stake in Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the transaction, the insider directly owned 134,643 shares of the company’s stock, valued at approximately $36,744,074.70. This represents a 2.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,872 shares of company stock valued at $39,627,696 over the last ninety days. 5.05% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on NTRA shares. Canaccord Genuity Group raised their price target on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Morgan Stanley raised their target price on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Natera in a report on Monday, July 6th. Finally, Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Stock Performance

NTRA stock opened at $262.63 on Tuesday. The company has a fifty day moving average price of $235.24 and a 200-day moving average price of $220.56. The company has a market capitalization of $37.61 billion, a P/E ratio of -161.12 and a beta of 1.51. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.